-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Akebia Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q1 2017 to Q3 2024.
- Akebia Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2024 was -0.1 USD/shares, a 25% decline year-over-year.
- Akebia Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was -0.22 USD/shares, a 31.3% increase year-over-year.
- Akebia Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -0.28 USD/shares, a 46.2% increase from 2022.
- Akebia Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -0.52 USD/shares, a 69.4% increase from 2021.
- Akebia Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was -1.7 USD/shares, a 38.8% increase from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)